IBEX is transforming itself from a research and development company to a specialty pharmaceutical company focusing on the Canadian market place. IBEX has recently announced an agreement to buy Garvinci Inc., a private Canadian company with products in arthritis and women's heath.
IBEX 's strategy is to in-license additional products in the arthritis and women's health areas. Products of interest are products which have been approved (or are near-to-approval) in other jurisdictions.
IBEX currently markets a series of arthritis assays which are widely used in the pharmaceutical research market. IBEX is in the process of closing a transaction which will add three injectable medical devices, Oestenil (currently marketed), an injectable visco-supplement product to relieve the symptomatic pain associated with osteoarthritis of the hip, shoulder and knee; Ostenil-Mini, a line extension of Ostenil for small joints, and Viscoseal, a new injectable product for the management of pain following arthroscopy. Both of the latter medical devices require the approval of Health Canada and regulatory submission is expected in the within six months and approval within twelve.
The pipeline also includes an oral interleukin I inhibitor for the symptomatic relief of osteoarthritis which has been on the market in more than 20 countries and for which the Canadian filing for approval is expected in the next 24 months.
As a result of the Garvinci transaction, IBEX will also have the Canadian rights to NorLevo, a morning after pill which has been recently approved in Canada and for which the launch is expected in the second half of 2007.
IBEX also markets a series of proprietary enzymes (heparinases and chondroitinases) for research use, as well Heparinase I which is used in many leading hemostasis monitoring devices.
Last Updated: 04-19-2007